Navigating the New Antipsychotic Quality Measure: Compliance, Coding, and Five-Star Impact
The January 2026 CMS revisions to the Long-Stay Antipsychotic Quality Measure—now incorporating Medicare Fee-for-Service, Medicaid, and Medicare Advantage claims—create a more expansive and sensitive methodology that can trigger the measure even when antipsychotics were not administered during the MDS look-back period. This shift, combined with CMS concerns around underreporting and inaccurate diagnosis coding, places heightened pressure...
Register Now: Webinar on Upcoming Regulatory Changes on Chemical Restraints and Psychotropic Medications
Join Pathway Health experts for a timely and insightful discussion on the upcoming regulatory changes on chemical restraints and psychotropic medications, which will be part of the April 28, 2025, Appendix PP changes.About the Session:The Centers for Medicare and Medicaid Services (CMS) has updated regulations and guidance concerning the unnecessary use of psychotropic medications (F758)...